GOLDMAN SACHS GROUP INC - Y-MABS THERAPEUTICS INC ownership

Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 118 filers reported holding Y-MABS THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of Y-MABS THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$2,121,941
-22.4%
389,347
-3.3%
0.00%
-100.0%
Q2 2023$2,734,000
+186.0%
402,651
+111.0%
0.00%
Q1 2023$955,863
-38.2%
190,791
-39.8%
0.00%
Q4 2022$1,546,237
-41.4%
316,852
+73.1%
0.00%
-100.0%
Q3 2022$2,640,000
+15.0%
183,077
+20.7%
0.00%0.0%
Q2 2022$2,296,000
+53.3%
151,726
+20.3%
0.00%
Q1 2022$1,498,000
-57.5%
126,111
-42.0%
0.00%
-100.0%
Q4 2021$3,523,000
-84.8%
217,361
-73.3%
0.00%
-80.0%
Q3 2021$23,213,000
-16.3%
813,355
-0.9%
0.01%
-16.7%
Q2 2021$27,733,000
+12.1%
820,482
+0.3%
0.01%0.0%
Q1 2021$24,732,000
-42.0%
817,849
-5.1%
0.01%
-45.5%
Q4 2020$42,650,000
+53.0%
861,438
+18.6%
0.01%
+37.5%
Q3 2020$27,876,000
+11.3%
726,117
+25.2%
0.01%0.0%
Q2 2020$25,050,000
+94.0%
579,878
+17.2%
0.01%
+60.0%
Q1 2020$12,910,000
-28.4%
494,641
-14.3%
0.01%0.0%
Q4 2019$18,026,000
+163.5%
576,846
+119.8%
0.01%
+150.0%
Q3 2019$6,840,000
+32.4%
262,456
+16.2%
0.00%
+100.0%
Q2 2019$5,166,000
-12.3%
225,867
+0.5%
0.00%
-50.0%
Q1 2019$5,891,000
+21.8%
224,765
-5.5%
0.00%0.0%
Q4 2018$4,836,000
-41.5%
237,778
-23.6%
0.00%0.0%
Q3 2018$8,266,000311,2100.00%
Other shareholders
Y-MABS THERAPEUTICS INC shareholders Q1 2021
NameSharesValueWeighting ↓
Memorial Sloan Kettering Cancer Center 216,916$6,191,0003.86%
Sofinnova Investments, Inc. 2,194,278$62,625,0003.71%
MPM BioImpact LLC 452,970$12,928,0002.00%
Soleus Capital Management, L.P. 265,700$7,583,0001.18%
ASHFORD CAPITAL MANAGEMENT INC 452,110$12,903,0001.17%
ORACLE INVESTMENT MANAGEMENT INC 315,642$9,008,0001.12%
First Light Asset Management, LLC 577,663$16,487,0001.09%
Lombard Odier Asset Management (Switzerland) SA 352,839$10,070,0000.62%
Cormorant Asset Management, LP 500,000$14,270,0000.58%
Artal Group S.A. 400,000$11,416,0000.26%
View complete list of Y-MABS THERAPEUTICS INC shareholders